Does Rallies show Form 4 insider transactions for GYRE?

Yes. Rallies tracks GYRE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is GYRE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for GYRE. It does not provide personalized investment advice.

GYRE (Gyre Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Gyre Therapeutics, Inc. Common Stock (GYRE) is a publicly traded Healthcare sector company. As of May 21, 2026, GYRE trades at $6.10 with a market cap of $624.86M and a P/E ratio of 100.58. GYRE moved -3.35% today. Year to date, GYRE is -23.74%; over the trailing twelve months it is -47.02%. Its 52-week range spans $6.01 to $19.00. Analyst consensus is buy with an average price target of $19.00. Rallies surfaces GYRE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading GYRE stock inside the company?

Recent GYRE insider activity includes Luo Ying sold 10.14K, Luo Ying sold 179, Ma Songjiang sold 558, Ma Songjiang sold 2.00K, and Ma Songjiang sold 182. Rallies tracks insider transaction dates, shares, prices, and estimated values.

GYRE Key Metrics

Key financial metrics for GYRE
Metric	Value
Price	$6.10
Market Cap	$624.86M
P/E Ratio	100.58
EPS	$0.06
Dividend Yield	0.24%
52-Week High	$19.00
52-Week Low	$6.01
Volume	120
Avg Volume	0
Revenue (TTM)	$116.59M
Net Income	$9.88M
Gross Margin	95.36%

Recent GYRE Insider Trades

Luo Ying sold 10.14K (~$81.49K) on May 6, 2026.
Luo Ying sold 179 (~$1.43K) on May 5, 2026.
Ma Songjiang sold 558 (~$5.62K) on May 28, 2025.
Ma Songjiang sold 2.00K (~$20.56K) on May 27, 2025.
Ma Songjiang sold 182 (~$1.86K) on May 23, 2025.

Latest GYRE News

Gyre Therapeutics Posts Q1 $22.5M Revenue, Affirms $100.5–$111M Guidance — May 7, 2026
Gyre Therapeutics Acquires Cullgen for $300 Million, Builds US-China Biopharma Platform — May 4, 2026
Gyre Therapeutics Posts 10% Revenue Growth to $116.6M, Acquires Cullgen for $300M — Mar 12, 2026

GYRE Analyst Consensus

2 analysts cover GYRE: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $19.00.

Common questions about GYRE

Who is trading GYRE stock inside the company?: Recent GYRE insider activity includes Luo Ying sold 10.14K, Luo Ying sold 179, Ma Songjiang sold 558, Ma Songjiang sold 2.00K, and Ma Songjiang sold 182. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for GYRE?: Yes. Rallies tracks GYRE insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is GYRE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for GYRE. It does not provide personalized investment advice.